MX2023003432A - Formulaciones orodispersables. - Google Patents

Formulaciones orodispersables.

Info

Publication number
MX2023003432A
MX2023003432A MX2023003432A MX2023003432A MX2023003432A MX 2023003432 A MX2023003432 A MX 2023003432A MX 2023003432 A MX2023003432 A MX 2023003432A MX 2023003432 A MX2023003432 A MX 2023003432A MX 2023003432 A MX2023003432 A MX 2023003432A
Authority
MX
Mexico
Prior art keywords
orodispersible
formulations
orodispersible formulations
progestogen
friability
Prior art date
Application number
MX2023003432A
Other languages
English (en)
Inventor
Ryan Loughlin
Roger M Boissonneault
Original Assignee
Millicent Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millicent Pharma Ltd filed Critical Millicent Pharma Ltd
Publication of MX2023003432A publication Critical patent/MX2023003432A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Una formulación orodispersable para anticoncepción o terapia de reemplazo hormonal, que contiene un estrógeno y un progestágeno, que tiene suficiente dureza, tiempo de desintegración y friabilidad.
MX2023003432A 2020-09-29 2021-06-24 Formulaciones orodispersables. MX2023003432A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063084723P 2020-09-29 2020-09-29
US202163172140P 2021-04-08 2021-04-08
PCT/IB2021/055633 WO2022069956A1 (en) 2020-09-29 2021-06-24 Orodispersible formulations

Publications (1)

Publication Number Publication Date
MX2023003432A true MX2023003432A (es) 2023-08-04

Family

ID=76730950

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023003432A MX2023003432A (es) 2020-09-29 2021-06-24 Formulaciones orodispersables.

Country Status (7)

Country Link
US (3) US20230346695A1 (es)
EP (1) EP4221693A1 (es)
JP (1) JP2023543953A (es)
AU (1) AU2021351921A1 (es)
CA (1) CA3194494A1 (es)
MX (1) MX2023003432A (es)
WO (1) WO2022069956A1 (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1531921A (zh) * 2003-03-21 2004-09-29 上海兴康医药研究开发有限公司 经粉末包衣的药物口腔速崩片及其制备方法
US8475838B2 (en) * 2005-06-03 2013-07-02 Sandoz Ag Rapidly-dissolving pharmaceutical composition for inhibiting ovulation
FR2898492B1 (fr) * 2006-03-15 2008-06-06 Pierre Fabre Medicament Sa Comprimes orodispersibles de domperidone
US20080113953A1 (en) * 2006-06-08 2008-05-15 Warner Chilcott Company, Inc. Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailability
WO2010146551A2 (en) * 2009-06-16 2010-12-23 Ranbaxy Laboratories Limited Orally disintegrating compositions comprising antihypertensive agents
CN102058604A (zh) * 2009-11-17 2011-05-18 北京万全阳光医学技术有限公司 一种含有地诺孕素和戊酸雌二醇的药物组合物及其制备方法
CN102885798B (zh) * 2011-07-21 2015-04-22 成都康弘药业集团股份有限公司 一种口腔崩解片
EA036278B1 (ru) * 2014-03-27 2020-10-21 Юсб Фархим С.А. Фармацевтическая композиция
ME03728B (me) * 2015-06-18 2021-01-20 Estetra Sprl Orodisperzibilna dozna jedinica koja sadrži komponentu estetrola
RS61777B1 (sr) * 2015-06-18 2021-06-30 Estetra Sprl Oralno-disperzibilna tableta koja sadrži estetrol

Also Published As

Publication number Publication date
WO2022069956A1 (en) 2022-04-07
JP2023543953A (ja) 2023-10-18
CA3194494A1 (en) 2022-04-07
US20230080934A1 (en) 2023-03-16
US20230346695A1 (en) 2023-11-02
AU2021351921A1 (en) 2023-04-06
EP4221693A1 (en) 2023-08-09
US20220331337A1 (en) 2022-10-20

Similar Documents

Publication Publication Date Title
MXPA01007411A (es) Composiciones y metodos para suministro mucoso.
MY149623A (en) Sprayable gel-type skin/mucosa-adhesive preparation and administration system using the preparation
MXPA05010196A (es) Nuevas formulaciones y su uso.
EP1768625A4 (en) COMPOSITIONS OF DELAYED RELEASE WITH PROGESTERONE RECEPTOR MODULATORS
MY139506A (en) Hiv replication inhibitors
HRP20050173A2 (en) Composition containing an androgenous 11?-halogensteroid and a progestational hormone, and male contraceptive based on said comosition
SG153645A1 (en) Hormone replacement therapy
MX2021012271A (es) Carbonato de magnesio reaccionado en superficie como material portador para la liberacion de uno o mas agente(s) activo(s) en una formulacion para el cuidado del hogar.
PH12021550675A1 (en) Sustained delivery of angiopoetin-like 3 polypeptides
HUP0402213A2 (hu) Propilénglikolmonokaprilátot tartalmazó szteroid hormontartalmú transzdermális terápiás rendszer
CR20220355A (es) Compuestos activos frente a receptores nucleares
MX2020011817A (es) Metodos para tratar el linfoma.
MX2021012708A (es) Formulaciones novedosas que comprenden melflufen.
PT1526856E (pt) Composição farmacêutica que compreende derivados do estretol para ser utilizada no tratamento do cancro
MX2022007265A (es) Compuestos activos frente a receptores nucleares.
MX2023003432A (es) Formulaciones orodispersables.
JO2178B1 (en) Treatment of invasive diseases, using selected anti-PAR materials
MX2023002671A (es) Formulaciones agradables.
PL345087A1 (en) A device and method for the treatment of erectile dysfunction
TW200507838A (en) Active substance combination comprising a 2,5-dihydroxybenzenesulfonic compound and a potassium ion channel modulator
Johansson Future developments in hormonal contraception
PH12018000077B1 (en) A pharmaceutical composition for neuropathic pain
PE20051035A1 (es) Hormonas de administracion transdermica que no necesitan potenciadores de penetracion
MX2020011321A (es) Profármacos de estrógeno y métodos de administración de profármacos de estrógeno.
MY128759A (en) Oral controlled release formulations